New Data for Thyroid Eye Disease Treatment Tepezza to Be Presented at AAO Virtual

Horizon Therapeutics announced new Tepezza (teprotumumab-trbw) data will be presented at the American Academy of Ophthalmology Annual Meeting, Nov. 13-15, 2020. Tepezza is the first and only medicine approved by the FDA for the treatment of Thyroid Eye Disease (TED) – a serious, progressive and vision-threatening rare autoimmune disease.¹

Tepezza data being presented at AAO 2020 Virtual include:

• Long-Term Assessment of Proptosis and Diplopia from the OPTIC Trial of Teprotumumab in Thyroid Eye Disease
  • Session: PA038, R. Douglas
  • Date: On Demand (oral presentation)

• Improvement in the Fellow Eye of Patients With TED: Pooled Analyses from the Teprotumumab Studies
  • Session: PO305, R. Douglas
  • Date: On Demand (scientific poster)

• Dysthyroid Optic Neuropathy Response to Teprotumumab: Early Response to Therapy
  • Session: PO307, C. Sears
  • Date: On Demand (scientific poster)
    Independent study

• What Every Ophthalmologist Should Know About Teprotumumab
  • Session: OCU03V, R. Douglas
  • Date: Friday, Nov. 13, 2020; 1:07 p.m. PT (live broadcast)

• Plastics: Biologics for Orbital Disease (teprotumumab)
  • Session: SYM17V, R. Douglas
  • Date: Sunday, Nov. 15, 2020; 2:05 p.m. PT (live broadcast)

In addition, Horizon will host a virtual product theater on Friday, Nov. 13 at 4:30 p.m. PT about Tepezza, featuring Raymond Douglas, MD, PhD, director of the Orbital and Thyroid Eye Disease Program, Cedars-Sinai Medical Center.

1. Barrio-Barrio J, et al. Graves’ Ophthalmopathy: VISA versus EUGOGO Classification, Assessment, and Management. Journal of Ophthalmopathy. 2015;2015:1-16.